JP2019535759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535759A5 JP2019535759A5 JP2019527449A JP2019527449A JP2019535759A5 JP 2019535759 A5 JP2019535759 A5 JP 2019535759A5 JP 2019527449 A JP2019527449 A JP 2019527449A JP 2019527449 A JP2019527449 A JP 2019527449A JP 2019535759 A5 JP2019535759 A5 JP 2019535759A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- pharmaceutically acceptable
- optionally
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 26
- 239000012453 solvate Substances 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 17
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 17
- 125000003107 substituted aryl group Chemical group 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 230000002062 proliferating effect Effects 0.000 claims 14
- 125000002252 acyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 claims 7
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 claims 7
- 108091000080 Phosphotransferase Proteins 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 102000020233 phosphotransferase Human genes 0.000 claims 7
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 150000002430 hydrocarbons Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical class C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425503P | 2016-11-22 | 2016-11-22 | |
| US62/425,503 | 2016-11-22 | ||
| PCT/US2017/063139 WO2018098367A1 (en) | 2016-11-22 | 2017-11-22 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535759A JP2019535759A (ja) | 2019-12-12 |
| JP2019535759A5 true JP2019535759A5 (enExample) | 2021-01-14 |
| JP7308146B2 JP7308146B2 (ja) | 2023-07-13 |
Family
ID=60703094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527449A Active JP7308146B2 (ja) | 2016-11-22 | 2017-11-22 | インターロイキン１受容体関連キナーゼの阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10975055B2 (enExample) |
| EP (1) | EP3544970B1 (enExample) |
| JP (1) | JP7308146B2 (enExample) |
| AU (1) | AU2017363313B2 (enExample) |
| CA (1) | CA3042731A1 (enExample) |
| WO (1) | WO2018098367A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US12698259B2 (en) | 2018-10-15 | 2026-08-04 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4061341A4 (en) * | 2019-11-22 | 2024-04-10 | The Regents of the University of California | CASPASE6 INHIBITORS AND USES THEREOF |
| US12590070B2 (en) | 2019-12-03 | 2026-03-31 | Samjin Pharmaceutical Co., Ltd. | Adamantane derivatives as inhibitors of focal adhesion kinase |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| CA3172830A1 (en) * | 2020-03-23 | 2021-09-30 | John M. Hatcher | Potent and selective irreversible inhibitors of irak1 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| EP4185568A1 (en) | 2020-07-24 | 2023-05-31 | The University of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US20240308980A1 (en) * | 2021-03-17 | 2024-09-19 | Merck Sharp & Dohme Llc | Heteroaryl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| WO2024011116A2 (en) * | 2022-07-07 | 2024-01-11 | Dana-Farber Cancer Institute, Inc. | Potent and selective irreversible inhibitors of irak1 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) * | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| JP6106685B2 (ja) * | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| EP3079682A4 (en) * | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| ES2728403T3 (es) * | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK |
| MX358346B (es) * | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| LT3221306T (lt) * | 2014-11-20 | 2020-03-10 | Merck Patent Gmbh | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas |
-
2017
- 2017-11-22 AU AU2017363313A patent/AU2017363313B2/en active Active
- 2017-11-22 WO PCT/US2017/063139 patent/WO2018098367A1/en not_active Ceased
- 2017-11-22 JP JP2019527449A patent/JP7308146B2/ja active Active
- 2017-11-22 US US16/462,200 patent/US10975055B2/en active Active
- 2017-11-22 EP EP17817469.4A patent/EP3544970B1/en active Active
- 2017-11-22 CA CA3042731A patent/CA3042731A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535749A5 (enExample) | ||
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| US11939320B2 (en) | Modulators of the integrated stress pathway | |
| AU2019290197B2 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| JP7355758B2 (ja) | ケモカイン受容体調節剤及びその使用 | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| JP2021105013A5 (enExample) | ||
| US20230144871A1 (en) | Modulators of the integrated stress pathway | |
| CN103626752B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| US20240018133A1 (en) | Modulators of the integrated stress pathway | |
| JP2012526838A5 (enExample) | ||
| EP3938038A1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| CA3080959A1 (en) | Modulators of the integrated stress pathway | |
| JP2016533379A5 (enExample) | ||
| JP2018526413A5 (enExample) | ||
| JP2016539138A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| JP2009541349A (ja) | プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン | |
| AU2020226633B2 (en) | Nurr1 receptor modulators | |
| JP2008500378A5 (enExample) | ||
| RU2013107659A (ru) | ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε | |
| RU2014143232A (ru) | Соединения для применения в лечении нейробластомы, саркомы юинга или рабдомиосаркомы | |
| JP2013521316A5 (enExample) | ||
| JP2017532371A5 (enExample) |